Noramco and Willow Biosciences to jointly develop a biosynthesis platform for synthetic CBD

New activity will add options and cost savings to Noramco’s robust CBD platform

Related Articles

FormattedPicture

NUTRITION & HEALTH NEWS

15 Nov 2019 --- In nutrition news this week, cannabidiol (CBD) is set to be classified as a novel food in Germany, while the Million Microbiome of Humans Project will analyze one... Read More

FormattedPicture

NUTRITION & HEALTH NEWS

11 Nov 2019 --- The UK’s National Institute for Health and Care Excellence (NICE) has recommended that some cannabis-based medicinal products (CBMP) receive routine... Read More

FormattedPicture

NUTRITION & HEALTH NEWS

06 Nov 2019 ---  One-time exposure to cannabinoids (CBs) – both synthetic and natural – during early pregnancy, can cause growth issues in developing embryos. This... Read More

FormattedPicture

NUTRITION & HEALTH NEWS

04 Nov 2019 --- Amid a market boom in cannabidiol (CBD) products, new research by the Grocery Manufacturers Association (GMA) has shown increased consumer confusion over what CBD... Read More

FormattedPicture

NUTRITION & HEALTH NEWS

22 Oct 2019 --- Equity funding company BIGR ventures has made a US$3 million Series A investment in organic Cannabidiol (CBD) brand RE Botanicals. The additional funding follows an... Read More

trans